Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III

The Phase III non-small cell lung cancer trial is not expected to demonstrate efficacy based on interim data, the firm says. Phase II studies in leukemia and various solid tumors are ongoing.